Company profile: JanOne
1.1 - Company Overview
Company description
- Provider of pharmaceutical drug candidates targeting severe pain conditions, including JAN101, a twice-daily slow-release oral sodium nitrite formulation for treatment and prevention of peripheral artery disease (PAD) and associated pain, and Jan123, a low-dose naltrexone candidate for complex regional pain syndrome delivered via a unique oral biphasic release tablet.
Products and services
- Pain Therapeutics Drug Development and Commercialization: Delivers pain-focused pharmaceutical R&D and commercialization, specifically identifying treatments for severe pain and bringing drugs to market
- Jan123: Develops a low dose naltrexone drug candidate to treat complex regional pain syndrome, delivered via a unique oral biphasic release tablet
- JAN101: Produces a twice-daily orally-dosed slow-release sodium nitrite formulation for the treatment and prevention of peripheral artery disease and associated pain
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to JanOne
Imcyse
HQ: Belgium
Website
- Description: Provider of clinical-stage biopharmaceutical R&D, pioneering active specific immunotherapies to treat severe, chronic autoimmune diseases. Its technology platform locally targets immune cells involved in the destruction of diseased organs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imcyse company profile →
Sigrid THx
HQ: Sweden
Website
- Description: Provider of ingested medical devices and platform technologies to lower blood sugar in prediabetics and newly diagnosed type 2 diabetics. Offerings include SiPore21 and the SiPore platform using engineered silica particles acting in the gut without absorption. Conducts clinical trials, including SiPore15 and SiPore21, with potential future indications in obesity, NASH, and infantile colic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sigrid THx company profile →
Thermalin
HQ: United States
Website
- Description: Provider of insulins and delivery systems that transform the economic, treatment, and disease management paradigms for diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Thermalin company profile →
Diasome
HQ: United States
Website
- Description: Provider of insulin-based, liver-targeted diabetes therapeutics utilizing Hepatocyte Directed Vesicles (HDV) to enhance insulin delivery and reduce hypoglycemia risk. The company conducts multiple Phase 2 studies, including OPTI-2 and ISLE-1 Phase 2b trials, the Good to Great study, and an insulin pump crossover study, evaluating HDV added to rapid-acting insulin in patients with Type 1 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diasome company profile →
Dexcom
HQ: United States
Website
- Description: Provider of continuous glucose monitoring systems and data services for diabetes management, developing, manufacturing and distributing Dexcom G7 (real-time readings and alerts, compatible with Apple Watch), Dexcom G6 (for users 2+), and the OTC Stelo Glucose Biosensor System for adults not on insulin, plus Dexcom Clarity for glucose data analysis and Dexcom Follow/Share for remote data sharing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dexcom company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for JanOne
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to JanOne
2.2 - Growth funds investing in similar companies to JanOne
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for JanOne
4.2 - Public trading comparable groups for JanOne
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →